
Join SOPHiA GENETICS™ and ARC Regulatory for an exclusive Industry Reception bringing together precision medicine and pharma leaders in Boston on July 21st.
Following our recently announced Master Collaboration Agreement, this event will spotlight our integrated solution for pharma companies across the clinical development lifecycle in Europe, combining ARC's IVDR regulatory expertise with SOPHiA GENETICS' NGS technology and CE-IVD track record.
You’ll hear directly from both teams about key milestones, including the co-development of a Clinical Trial Assay (CTA) designed to accelerate patient recruitment in European clinical trials.
Accelerate with Impact: Expanding Patient Access to Precision Medicine Across the EU
The programme will be followed by a networking reception, offering a unique opportunity to connect with peers and leaders shaping the future of precision medicine.
Reserve your spot today!
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.